Posted inCardiagtech

Diabetic Ketoacidosis Diagnosis Criteria: A Comprehensive Guide for Healthcare Professionals

No Comments

Diabetic ketoacidosis (DKA) stands as a severe and potentially life-threatening complication of diabetes mellitus, primarily arising from a critical deficiency of insulin coupled with an excess of counter-regulatory hormones. This imbalance leads to a cascade of metabolic disturbances characterized by hyperglycemia, metabolic acidosis, and ketonemia. While predominantly observed in individuals with type 1 diabetes, DKA can also affect those with type 2 diabetes under certain precipitating conditions. Prompt and accurate diagnosis based on established Diabetic Ketoacidosis Diagnosis Criteria is paramount for effective management and to mitigate adverse outcomes. This article delves into the essential aspects of DKA, focusing on the diagnostic criteria, evaluation, and management strategies crucial for healthcare professionals.

Etiology of Diabetic Ketoacidosis

Diabetic ketoacidosis primarily stems from an absolute or relative insulin deficiency. This deficiency is often exacerbated by factors such as new-onset diabetes, infections, or lapses in adherence to prescribed insulin therapy. In patients with type 1 diabetes, the lack of insulin is typically absolute due to autoimmune destruction of pancreatic beta cells. However, in type 2 diabetes, while insulin resistance is a primary feature, DKA can develop under conditions of significant metabolic stress.

Several factors can precipitate DKA across diabetes types. These include:

  • Infections: Pneumonia and urinary tract infections are among the most common infectious triggers.
  • New-onset diabetes: DKA can be the initial presentation of type 1 diabetes, and less commonly type 2 diabetes.
  • Non-compliance with insulin therapy: Missed insulin doses or inadequate insulin administration are significant risk factors, particularly in populations with socioeconomic challenges or limited health literacy.
  • Acute illnesses and stress: Conditions such as trauma, surgery, myocardial infarction, and pulmonary embolism can induce catabolic stress leading to DKA.
  • Medications: Certain drugs including corticosteroids, thiazide diuretics, sympathomimetic agents, pentamidine, and even some antipsychotics can disrupt carbohydrate metabolism and trigger DKA.
  • SGLT2 inhibitors: Paradoxically, these medications, while beneficial in managing hyperglycemia in type 2 diabetes, have been linked to an increased risk of euglycemic DKA. This occurs because SGLT2 inhibitors can promote glucagon secretion and reduce urinary ketone excretion, leading to ketoacidosis even with modestly elevated or near-normal glucose levels.
  • Substance abuse: Alcohol and cocaine abuse have been identified as independent risk factors for DKA, potentially due to their effects on metabolism and medication adherence.

Epidemiology of Diabetic Ketoacidosis

The incidence of diabetic ketoacidosis varies globally, ranging from 0 to 56 cases per 1000 person-years depending on geographic location and population characteristics. Certain demographic patterns have emerged:

  • Gender and Ethnicity: DKA prevalence is generally higher among women and non-White populations.
  • Insulin Delivery Method: Patients using injectable insulin are at a higher risk compared to those using subcutaneous insulin infusion pumps.
  • Age: While DKA can occur at any age, the prognosis tends to worsen at the extremes of age, particularly in the elderly and very young.
  • Geographic Variation: Incidence rates in children show significant international disparities, with the lowest rates in regions like Nigeria and the highest in Scandinavian countries like Sweden and Finland. This suggests a correlation with factors such as healthcare access and socioeconomic conditions.
  • Mortality: Overall mortality from DKA has decreased in developed countries, but remains a concern in older adults and those with co-existing severe illnesses. Mortality rates can exceed 5% in these vulnerable groups.
  • Socioeconomic Factors: In urban settings, insulin non-compliance, often linked to socioeconomic and educational disparities, is a leading cause of recurrent DKA. Substance abuse further complicates adherence to therapy.

Alt text: A medical professional is educating a patient about diabetes, highlighting the importance of understanding and managing the condition to prevent complications like diabetic ketoacidosis.

Pathophysiology of Diabetic Ketoacidosis

The pathophysiology of DKA is complex and involves a cascade of metabolic derangements initiated by insulin deficiency and glucagon excess.

  1. Hyperglycemia: Insulin deficiency impairs glucose uptake by peripheral tissues and fails to suppress hepatic glucose production. This results in increased gluconeogenesis (glucose production from non-carbohydrate sources) and glycogenolysis (breakdown of glycogen to glucose), leading to elevated blood glucose levels.

  2. Ketogenesis and Metabolic Acidosis: The lack of insulin promotes lipolysis, releasing free fatty acids from adipose tissue. These fatty acids are transported to the liver where they undergo beta-oxidation, producing ketone bodies (beta-hydroxybutyrate and acetoacetate). Ketone bodies are acidic and their accumulation leads to metabolic acidosis.

  3. Dehydration and Electrolyte Imbalance: Hyperglycemia induces osmotic diuresis as the kidneys attempt to excrete excess glucose. This leads to significant fluid and electrolyte loss, causing dehydration and hyperosmolarity. Electrolyte imbalances, particularly potassium depletion, are common due to both osmotic diuresis and intracellular shifts.

  4. Inflammatory Response: Emerging evidence suggests that hyperglycemia itself can trigger a systemic inflammatory response, with increased levels of pro-inflammatory cytokines. This inflammatory state may contribute to the severity of DKA and associated complications.

  5. Euglycemic DKA: In the context of SGLT2 inhibitors, DKA can occur with near-normal glucose levels (euglycemic DKA). This is attributed to the drug’s effects on glucagon secretion, ketone body excretion, and potentially altered insulin-to-glucagon ratios, favoring ketogenesis even without marked hyperglycemia.

History and Physical Examination in DKA

The clinical presentation of diabetic ketoacidosis can vary widely, from subtle early symptoms to severe, life-threatening decompensation. A thorough history and physical examination are crucial for prompt recognition and diagnosis.

History:

  • Symptoms of Hyperglycemia: Polyuria, polydipsia, polyphagia (increased hunger) are classic symptoms, though they may not be prominent in all patients, especially in acute presentations.
  • Dehydration Symptoms: Decreased urine output, dry mouth, reduced sweating, dizziness, and weakness indicate volume depletion.
  • Gastrointestinal Symptoms: Anorexia, nausea, vomiting, and abdominal pain are common, and abdominal pain can sometimes be severe, mimicking acute abdomen.
  • Infectious Symptoms: Fever, cough, urinary symptoms, or other signs of infection should be sought as infection is a common precipitating factor.
  • Neurological Symptoms: Headache, confusion, drowsiness, and altered mental status may indicate cerebral edema, a critical complication.
  • Medication History: Inquire about diabetes medications, adherence, and any new medications, especially SGLT2 inhibitors or corticosteroids.
  • Substance Use History: Assess alcohol and drug use, as these can contribute to DKA and affect management.

Physical Examination:

  • Vital Signs: Tachycardia (rapid heart rate) and tachypnea (rapid breathing) are typical. Hypotension (low blood pressure) suggests significant dehydration and a more severe condition. Fever or hypothermia may be present, depending on the underlying cause.
  • General Appearance: Patients often appear ill and may be lethargic or obtunded.
  • Respiratory Examination: Kussmaul breathing—deep, labored, and rapid respirations—is a classic sign of metabolic acidosis as the body attempts to compensate by blowing off carbon dioxide. A fruity odor on the breath, due to acetone, may be detectable.
  • Hydration Status: Assess for dehydration signs: poor skin turgor, dry mucous membranes, and delayed capillary refill.
  • Abdominal Examination: Abdominal tenderness may be present, even in the absence of intra-abdominal pathology.
  • Neurological Examination: Evaluate mental status carefully. Altered mental status, drowsiness, or focal neurological deficits are concerning for cerebral edema and require immediate attention.

Evaluation and Diabetic Ketoacidosis Diagnosis Criteria

The diagnosis of diabetic ketoacidosis relies on a combination of clinical presentation and specific laboratory findings. The universally accepted diabetic ketoacidosis diagnosis criteria include:

  1. Hyperglycemia: Blood glucose level greater than 250 mg/dL (13.9 mmol/L). It’s important to note that in euglycemic DKA, glucose levels may be lower than this threshold, sometimes even within the normal range.

  2. Metabolic Acidosis:

    • Arterial pH less than 7.3. Venous pH is often used in clinical practice and a value <7.3 also suggests acidosis.
    • Serum bicarbonate level less than 15 mEq/L.

  3. Ketonemia or Ketonuria: Presence of ketones in serum or urine. Ketonemia is a more direct and quantitative measure.

In addition to these core criteria, several other laboratory parameters are crucial in the evaluation and management of DKA:

  • Anion Gap: Calculated as [Sodium – (Chloride + Bicarbonate)]. A normal anion gap is approximately 12 mEq/L. In DKA, the anion gap is typically elevated (>14-15 mEq/L) due to the accumulation of ketoacids.
  • Serum Electrolytes:
    • Sodium: Serum sodium is often falsely low in DKA due to hyperglycemia-induced osmotic shift of water from intracellular to extracellular space. Corrected sodium can be estimated by adding 1.6 mEq/L to measured sodium for every 100 mg/dL glucose above 100 mg/dL.
    • Potassium: Initial serum potassium may be normal or even elevated due to acidosis-induced extracellular shift. However, total body potassium is usually depleted, and insulin therapy will drive potassium intracellularly, potentially causing hypokalemia.
    • Magnesium and Phosphate: Levels of these electrolytes are often low and may require repletion.
  • Complete Blood Count (CBC): Leukocytosis (elevated white blood cell count) is common, even in the absence of infection.
  • Renal Function Tests: Blood urea nitrogen (BUN) and creatinine may be elevated due to dehydration and potential kidney injury.
  • Glycated Hemoglobin (A1C): Provides information about long-term glycemic control and can help differentiate new-onset diabetes from pre-existing diabetes with DKA.
  • Ketone Body Measurement:
    • Nitroprusside test: Traditionally used to detect acetoacetate in urine and serum. It is semi-quantitative and can have false positives and negatives.
    • Beta-hydroxybutyrate (3-HB) assay: Quantitative blood tests for 3-HB are now readily available and provide a more accurate assessment of ketosis. 3-HB is the predominant ketone body in DKA, and its levels correlate better with disease severity and response to treatment.
  • Pancreatic Enzymes: Serum amylase and lipase may be elevated in DKA, even without pancreatitis. Elevations are usually mild to moderate and should be interpreted cautiously in the context of DKA. If pancreatitis is suspected, imaging studies like CT scans are necessary.
  • Electrocardiogram (ECG): To assess for ischemic changes and electrolyte abnormalities, particularly hyperkalemia (peaked T waves) or hypokalemia (U waves, flattened T waves).
  • Chest X-ray: To rule out pneumonia if infection is suspected as a precipitating factor.
  • Head Imaging (CT or MRI): Considered if cerebral edema is suspected based on neurological symptoms, but should not delay immediate treatment.

Alt text: A representation of lab results indicative of diabetic ketoacidosis, highlighting key markers such as elevated blood glucose, low pH, reduced bicarbonate, and presence of ketones.

Treatment and Management of Diabetic Ketoacidosis

The management of DKA is a medical emergency requiring prompt and aggressive intervention. The main goals of treatment are to correct dehydration, hyperglycemia, electrolyte imbalances, and acidosis.

  1. Fluid Resuscitation: Dehydration is a significant component of DKA. Initial fluid replacement aims to restore intravascular volume, improve tissue perfusion, and facilitate ketone clearance.

    • Initial Fluid: Isotonic saline (0.9% NaCl) is the standard initial fluid.
    • Rate of Infusion: Typically, 15-20 mL/kg of body weight over the first hour. Aggressive hydration may be needed in hypotensive patients.
    • Maintenance Fluids: Subsequent fluid choice depends on serum sodium levels. 0.45% NaCl is used if serum sodium is high, and 0.9% NaCl if sodium is normal or low. Ringer’s lactate can be considered if hyperchloremic acidosis becomes a concern.

  2. Insulin Therapy: Insulin is crucial to suppress ketogenesis and correct hyperglycemia.

    • Route: Intravenous continuous infusion of regular insulin is the standard.
    • Initial Dose: A bolus dose is generally not required. Start with a continuous infusion of 0.1 U/kg/hour.
    • Glucose Correction: When blood glucose reaches 200-250 mg/dL, add dextrose to intravenous fluids (e.g., D5W or D10W) to prevent hypoglycemia and continue insulin infusion at a reduced rate to resolve ketoacidosis.
    • Subcutaneous Insulin: In mild to moderate DKA, subcutaneous rapid-acting insulin analogs (lispro or aspart) may be an alternative to intravenous insulin in non-ICU settings.

  3. Electrolyte Replacement:

    • Potassium: Potassium replacement is almost always necessary. Start replacement when serum potassium is < 5.2 mEq/L, aiming to maintain levels between 4-5 mEq/L. If initial potassium is < 3.3 mEq/L, delay insulin and prioritize potassium replacement to prevent cardiac arrhythmias.
    • Magnesium: Replete magnesium if hypomagnesemia is present, as it can hinder potassium correction.
    • Bicarbonate: Routine bicarbonate administration is generally not recommended and may be harmful. It may be considered in severe acidosis (pH < 7.1) but should be used cautiously due to potential risks like paradoxical CSF acidosis and hypokalemia.
    • Phosphate: Phosphate replacement is usually not routinely needed, but may be considered in severe hypophosphatemia.

  4. Monitoring:

    • Blood Glucose: Hourly point-of-care testing.
    • Serum Electrolytes and Glucose: Every 2 hours initially, then every 4 hours as the patient stabilizes.
    • Venous or Arterial Blood Gas (VBG/ABG): Initially and as needed to monitor acidosis resolution.
    • BUN, Creatinine, and other relevant labs: Monitor renal function and overall metabolic status.

  5. Management of Precipitating Factors: Identify and treat underlying triggers like infections.

  6. Cerebral Edema Management: Recognize and treat cerebral edema promptly. Mannitol or hypertonic saline (3% NaCl) are first-line treatments.

  7. Intubation and Ventilation: Avoid intubation if possible. If necessary due to respiratory failure or altered mental status compromising airway protection, carefully manage ventilation to match the patient’s pre-intubation minute ventilation to avoid worsening acidosis.

Resolution of DKA: DKA is considered resolved when the following criteria are met:

  • Blood glucose < 200 mg/dL
  • At least two of the following:
    • Serum bicarbonate ≥ 15 mEq/L
    • Venous pH > 7.3
    • Calculated anion gap ≤ 12 mEq/L

Once DKA is resolved and the patient can eat, transition to subcutaneous insulin. Continue intravenous insulin infusion for 1-2 hours after the first subcutaneous insulin dose to prevent rebound hyperglycemia and ketoacidosis.

Differential Diagnosis of Diabetic Ketoacidosis

Several conditions can mimic DKA, requiring careful differential diagnosis:

  • Hyperosmolar Hyperglycemic State (HHS): Another hyperglycemic emergency in diabetes, but characterized by more profound hyperosmolarity and less prominent ketosis and acidosis.
  • Starvation Ketosis: Mild ketosis due to prolonged fasting, typically without significant hyperglycemia or acidosis.
  • Alcoholic Ketoacidosis: Ketoacidosis in the context of chronic alcohol abuse, often with hypoglycemia or mild hyperglycemia.
  • Lactic Acidosis: Elevated lactate levels causing metabolic acidosis, can be due to sepsis, hypoperfusion, or other causes.
  • Sepsis: Can present with metabolic acidosis and altered mental status, but usually with signs of infection and without significant hyperglycemia and ketosis (unless in a diabetic patient).
  • Toxic ingestions: Ethylene glycol, methanol, salicylate, and paraldehyde poisoning can cause metabolic acidosis.
  • Diabetic medication overdose: Especially sulfonylureas, can cause hypoglycemia, but not typically ketoacidosis.
  • Pancreatitis: Can cause abdominal pain and elevated amylase/lipase, potentially mimicking DKA-related abdominal pain.
  • Myocardial Infarction: Can present with acute illness and altered metabolic state, though less likely to directly mimic DKA.
  • Uremia: Metabolic acidosis in the setting of kidney failure.

Prognosis and Complications of Diabetic Ketoacidosis

With prompt and appropriate treatment, the prognosis for DKA is generally good in developed countries, with mortality rates below 1%. However, certain factors worsen prognosis:

  • Coma on presentation
  • Hypothermia
  • Oliguria or renal dysfunction
  • Advanced age
  • Coexisting severe illnesses (e.g., myocardial infarction, sepsis, pneumonia)
  • Cerebral edema (especially in children and adolescents)

Complications of DKA and its treatment include:

  • Hypoglycemia: A common complication during treatment, requiring careful glucose monitoring and adjustment of insulin and dextrose infusion rates.
  • Hypokalemia: Can occur rapidly with insulin therapy and can lead to cardiac arrhythmias and muscle weakness.
  • Electrolyte imbalances: Hyperchloremia, hypomagnesemia, hypophosphatemia, and hyponatremia can occur.
  • Cerebral edema: A rare but devastating complication, more common in children and adolescents.
  • Rhabdomyolysis: Muscle breakdown, can occur, particularly in severe cases, and may lead to acute kidney injury.
  • Acute respiratory failure: Due to pneumonia, ARDS, or pulmonary edema (both cardiogenic and non-cardiogenic).
  • Thrombotic Thrombocytopenic Purpura (TTP) and myocarditis: Rare, but reported associations.

Deterrence and Patient Education

Patient education is critical in preventing DKA. Key aspects include:

  • Comprehensive diabetes education, covering disease process, short and long-term complications.
  • Training on blood glucose monitoring techniques and frequency.
  • Education on diabetes medications (oral agents and insulin), their proper use, side effects, and the importance of adherence.
  • Sick-day management education: advising patients on how to adjust insulin doses and increase fluid intake during illness to prevent DKA.
  • Emphasis on recognizing early symptoms of hyperglycemia and DKA, and seeking prompt medical attention.

Enhancing Healthcare Team Outcomes

Optimal management of diabetic ketoacidosis requires a collaborative interprofessional team approach. Key team members include:

  • Emergency Department (ED) Team: Triage nurses, ED physicians, and support staff are the first point of contact and initiate resuscitation and initial management.
  • Intensivists and Endocrinologists: Provide expertise in managing complex metabolic derangements and guide treatment strategies.
  • Nurses: Crucial for continuous monitoring, medication administration, electrolyte replacement, and patient education.
  • Pharmacists: Ensure appropriate medication dosing and electrolyte management, and identify potential drug-related issues.
  • Radiologists: Provide timely interpretation of imaging studies when needed.
  • Infectious Disease and Cardiology Consultants: Consulted if infection or cardiac events are suspected as triggers.
  • Social Workers: Address socioeconomic barriers to care, medication adherence, and facilitate discharge planning and follow-up, especially for patients with recurrent DKA.
  • Dietitians and Diabetes Educators: Provide comprehensive diabetes education and dietary counseling for long-term management and prevention of recurrence.

Streamlined communication, clear protocols, and coordinated care are essential to improve outcomes and reduce morbidity and mortality associated with diabetic ketoacidosis.

Review Questions

(Note: Review questions are present in the original article, but are not included in this rewritten version as per instructions.)

References

(Note: References from the original article are retained for completeness and academic integrity.)

  1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43. [PMC free article: PMC2699725] [PubMed: 19564476]
  2. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52. [PMC free article: PMC4525004] [PubMed: 26086329]
  3. Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017;2017 [PMC free article: PMC5592704] [PubMed: 28924481]
  4. Gosmanov AR, Kitabchi AE. Diabetic Ketoacidosis. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Apr 28, 2018. [PubMed: 25905369]
  5. Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017 Aug 01;7(7):e016587. [PMC free article: PMC5642652] [PubMed: 28765134]
  6. Große J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U. Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates with Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression. Horm Metab Res. 2018 Mar;50(3):209-222. [PubMed: 29523007]
  7. Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O’Sullivan PS. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med. 1991 Nov-Dec;6(6):495-502. [PubMed: 1765864]
  8. Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med. 1997 Mar 24;157(6):669-75. [PubMed: 9080921]
  9. Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality – United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):362-365. [PMC free article: PMC5877353] [PubMed: 29596400]
  10. Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002. Diabetes Care. 2006 Sep;29(9):2018-22. [PubMed: 16936146]
  11. Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am. 2004 Jul;88(4):1063-84, xii. [PubMed: 15308390]
  12. Philippe J. Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7224-7. [PMC free article: PMC52266] [PubMed: 1651499]
  13. Barnes AJ, Bloom SR, Goerge K, Alberti GM, Smythe P, Alford FP, Chisholm DJ. Ketoacidosis in pancreatectomized man. N Engl J Med. 1977 Jun 02;296(22):1250-3. [PubMed: 404553]
  14. Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. Lancet. 1973 Sep 22;2(7830):635-9. [PubMed: 4125618]
  15. Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care. 2002 Mar;17(1):63-7. [PubMed: 12040551]
  16. Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am. 1995 Jan;79(1):39-52. [PubMed: 7808094]
  17. Umpierrez GE, Khajavi M, Kitabchi AE. Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Am J Med Sci. 1996 May;311(5):225-33. [PubMed: 8615398]
  18. Paulson WD, Gadallah MF. Diagnosis of mixed acid-base disorders in diabetic ketoacidosis. Am J Med Sci. 1993 Nov;306(5):295-300. [PubMed: 8238083]
  19. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001 Jan;24(1):131-53. [PubMed: 11194218]
  20. Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med. 1980 Aug;93(2):280-1. [PubMed: 6773457]
  21. Warshaw AL, Feller ER, Lee KH. On the cause of raised serum-amylase in diabetic ketoacidosis. Lancet. 1977 Apr 30;1(8018):929-31. [PubMed: 67388]
  22. Vantyghem MC, Haye S, Balduyck M, Hober C, Degand PM, Lefebvre J. Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes. Acta Diabetol. 1999 Jun;36(1-2):39-44. [PubMed: 10436251]
  23. Weidman SW, Ragland JB, Fisher JN, Kitabchi AE, Sabesin SM. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. J Lipid Res. 1982 Jan;23(1):171-82. [PubMed: 6799600]
  24. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000567. [PubMed: 23450531]
  25. Mahler SA, Conrad SA, Wang H, Arnold TC. Resuscitation with balanced electrolyte solution prevents hyperchloremic metabolic acidosis in patients with diabetic ketoacidosis. Am J Emerg Med. 2011 Jul;29(6):670-4. [PubMed: 20825879]
  26. Chua HR, Venkatesh B, Stachowski E, Schneider AG, Perkins K, Ladanyi S, Kruger P, Bellomo R. Plasma-Lyte 148 vs 0.9% saline for fluid resuscitation in diabetic ketoacidosis. J Crit Care. 2012 Apr;27(2):138-45. [PubMed: 22440386]
  27. Van Zyl DG, Rheeder P, Delport E. Fluid management in diabetic-acidosis–Ringer’s lactate versus normal saline: a randomized controlled trial. QJM. 2012 Apr;105(4):337-43. [PubMed: 22109683]
  28. Adrogué HJ, Barrero J, Eknoyan G. Salutary effects of modest fluid replacement in the treatment of adults with diabetic ketoacidosis. Use in patients without extreme volume deficit. JAMA. 1989 Oct 20;262(15):2108-13. [PubMed: 2507798]
  29. Edge JA, Jakes RW, Roy Y, Hawkins M, Winter D, Ford-Adams ME, Murphy NP, Bergomi A, Widmer B, Dunger DB. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia. 2006 Sep;49(9):2002-9. [PubMed: 16847700]
  30. Gosmanov AR, Gosmanova EO, Kitabchi AE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): May 9, 2021. [PubMed: 25905280]
  31. Kitabchi AE, Murphy MB, Spencer J, Matteri R, Karas J. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis? Diabetes Care. 2008 Nov;31(11):2081-5. [PMC free article: PMC2571050] [PubMed: 18694978]
  32. Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, E Kitabchi A. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004 Sep 01;117(5):291-6. [PubMed: 15336577]
  33. Razavi Z, Maher S, Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine. 2018 Aug;61(2):267-274. [PubMed: 29797212]
  34. Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016 Apr;65(4):507-21. [PubMed: 26975543]
  35. Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014 Nov;37(11):3124-31. [PMC free article: PMC4207202] [PubMed: 25342831]
  36. Herpes virus fingerprinting. Lancet. 1979 Feb 03;1(8110):251-2. [PubMed: 84904]
  37. Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017 May;101(3):587-606. [PMC free article: PMC6535398] [PubMed: 28372715]
  38. Duhon B, Attridge RL, Franco-Martinez AC, Maxwell PR, Hughes DW. Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis. Ann Pharmacother. 2013 Jul-Aug;47(7-8):970-5. [PubMed: 23737516]
  39. Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle K, Roback M, Malley R, Kuppermann N., Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. 2001 Jan 25;344(4):264-9. [PubMed: 11172153]
  40. Osuka A, Matsuoka T, Idoguchi K. Is this the worst outcome of metabolic syndrome? Hypophosphatemia and resulting cardiac arrest during the treatment of diabetic ketoacidosis with hypertriglyceridemia. Intern Med. 2009;48(16):1391-5. [PubMed: 19687585]
  41. Regmi A, Konstantinov NK, Agaba EI, Rohrscheib M, Dorin RI, Tzamaloukas AH. Respiratory Failure in the Course of Treatment of Diabetic Ketoacidosis. Clin Diabetes. 2014 Jan;32(1):28-31. [PMC free article: PMC4521429] [PubMed: 26246676]
  42. Abbas Q, Arbab S, Haque AU, Humayun KN. Spectrum of complications of severe DKA in children in pediatric Intensive Care Unit. Pak J Med Sci. 2018 Jan-Feb;34(1):106-109. [PMC free article: PMC5856992] [PubMed: 29643888]
  43. Kutlu AO, Kara C, Cetinkaya S. Rhabdomyolysis without detectable myoglobulinuria due to severe hypophosphatemia in diabetic ketoacidosis. Pediatr Emerg Care. 2011 Jun;27(6):537-8. [PubMed: 21642790]
  44. Konstantinov NK, Rohrscheib M, Agaba EI, Dorin RI, Murata GH, Tzamaloukas AH. Respiratory failure in diabetic ketoacidosis. World J Diabetes. 2015 Jul 25;6(8):1009-23. [PMC free article: PMC4515441] [PubMed: 26240698]

Disclosures:

(Note: Disclosures from the original article are retained.)

Disclosure: Jenna Lizzo declares no relevant financial relationships with ineligible companies.

Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies.

Disclosure: Vikas Gupta declares no relevant financial relationships with ineligible companies.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *